Trial Profile
Treatment of Psoriatic Arthritis With hOKT3γ1 (Ala-Ala)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Teplizumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- 20 Mar 2012 Actual patient number is 4 according to ClinicalTrials.gov.
- 20 Oct 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 20 Nov 2005 New trial record.